Glycomine raises $115M to advance first-in-class PMM2-CDG therapy GLM101 into Phase 2b trial

San Carlos, CA, April 16, 2025 (Glycomine) -- Glycomine has secured $115 million in Series C financing to fund a Phase 2b trial of GLM101, its novel therapy for PMM2-CDG. The drug showed promising improvements in ataxia during an ongoing Phase 2 study. New and existing investors are backing the effort to bring the first disease-modifying treatment to patients with this rare condition.

Read full article here.